The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | REFINE: Phase II study of navitoclax + ruxolitinib in JAK inhibitor-naive patients with MF
Francesco Passamonti, MD, University of Insubria, Varese, Italy, comments on the results of REFINE, a Phase II study evaluating the safety and efficacy of navitoclax plus ruxolitinib in patients with myelofibrosis (MF) (NCT03222609). The primary endpoint of spleen volume reduction of ≥35% (SVR35) at week 24 was achieved in 52% of patients. The study also reported a reduction in bone marrow fibrosis and JAK2 mutant allele burden. Prof. Passamonti explains that the most common adverse events included hematological and gastrointestinal toxicities, and all toxicities were manageable. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
